Sign In
Buy BPTH
$0.0300
+0.0066 (+28.21%)
At Close: Jun 03, 2026
All You Need to Know About Bio-Path (BPTH) Rating Upgrade to Buy
01:00pm, Wednesday, 20'th Nov 2024
Bio-Path (BPTH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Bio-Path (BPTH) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
10:55am, Wednesday, 20'th Nov 2024
Bio-Path (BPTH) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a tr
Bio-Path Holdings, Inc. (BPTH) Q3 2024 Earnings Call Transcript
09:26am, Friday, 15'th Nov 2024
Bio-Path Holdings, Inc. (NASDAQ:BPTH ) Q3 2024 Earnings Conference Call November 15, 2024 8:30 AM ET Company Participants Will O'Connor - Managing Director & Team Lead, Stern Investor Relations Peter
Bio-Path Holdings Reports Third Quarter 2024 Financial Results
07:00am, Friday, 15'th Nov 2024
Expands DNAbilize ® Technology Beyond Oncology into Obesity Conference Call to be Held Today at 8:30 A.M. ET HOUSTON, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biote
Bio-Path Holdings to Announce Third Quarter 2024 Financial Results on November 15, 2024
07:00am, Friday, 08'th Nov 2024
HOUSTON, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a po
Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
05:24pm, Thursday, 10'th Oct 2024
HOUSTON, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc. (NASDAQ:BPTH) (“Bio-Path” or the “Company”), a biotechnology company leveraging its proprietary DNAbilize® liposomal deliver
Bio-Path Holdings Announces $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
08:00pm, Tuesday, 08'th Oct 2024
HOUSTON, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc. (NASDAQ:BPTH) (“Bio-Path” or the “Company”), a biotechnology company leveraging its proprietary DNAbilize® liposomal deliver
Bio-Path Holdings Initiates Development of Therapeutic Program for Treatment of Obesity
07:00am, Tuesday, 08'th Oct 2024
HOUSTON, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q2 24
05:48pm, Wednesday, 04'th Sep 2024
Dallas, Texas--(Newsfile Corp. - September 4, 2024) - Bio-Path Holdings, Inc. (NASDAQ: BPTH): Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH) for Q2 2024. To view
Bio-Path Holdings to Present at H.C. Wainwright 26th Annual Global Investment Conference
07:00am, Tuesday, 03'rd Sep 2024
HOUSTON, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develo
Bio-Path Holdings Reports Second Quarter 2024 Financial Results
07:00am, Thursday, 15'th Aug 2024
HOUSTON, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a po
Bio-Path Holdings to Announce Second Quarter 2024 Financial Results on August 15, 2024
07:00am, Thursday, 08'th Aug 2024
HOUSTON, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a po
Bio-Path Holdings Provides Clinical Update and Expansion Plans
07:00am, Monday, 08'th Jul 2024
Marks Meaningful Progress Across Key Clinical Trials in Multiple Cancer Indications Completes Development of Oncology Molecular Biomarkers and Prepares for Preclinical Obesity Studies HOUSTON, July 08
Why Is Bio-Path (BPTH) Stock Up 20% Today?
11:30am, Friday, 14'th Jun 2024
Bio-Path (NASDAQ: BPTH ) stock is rising higher on Friday alongside data from the oncology-focused company's Phase 2 clinical trial of prexigebersen. Prexigebersen is Bio-Path product candidate for t
Encore Presentation Highlights Positive Results from Interim Analysis Demonstrating Significant Clinical Improvement and Tolerable Safety Profile for Prexigebersen Combination in High-Risk Patients En
